The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...

Enfortumab vedotin and pembrolizumab combination offers transformative benefits, doubling median progression-free and overall survival in advanced urothelial carcinoma. The EV-302 trial showed a ...

A retrospective real-world study of disitamab vedotin combined with tislelizumab versus chemotherapy in patients with previously untreated metastatic urothelial carcinoma. Feasibility and efficacy of ...

Enfortumab vedotin, especially with pembrolizumab, shows promise with a 49% reduction in death risk compared to chemotherapy. The systematic review found a 66.2% objective response rate but a 58.4 ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.

Enfortumab vedotin-ejfv and pembrolizumab show superior PFS and OS compared to chemotherapy in urothelial carcinoma. The combination therapy's benefits are consistent across subgroups, including ...

Primary tumor response to enfortumab vedotin with/without pembrolizumab in patients with upper tract urothelial cancer. Upstaging and risk migration with blue light cystoscopy for non–muscle-invasive ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...